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Case report
A  72-year-old female patient with a  history of hy-
pertension was admitted to the hospital with suspicion 
of non-ST-segment elevation acute coronary syndrome. 
On ECG, left ventricle hypertrophy and negative T waves 
in V2–V6 were present. Levels of cardiac enzymes were 
markedly increased with troponin (Tn) I  at admission 
2.06 μg/l and with a  subsequent drop to values of 
0.99 μg/l and 0.71 μg/l. Renal function parameters were 
normal. She did not complain of chest pain, but due to 
long lasting diabetes treated with insulin silent myocar-
dial ischemia was suspected. At admission, an episode 
of supraventricular tachycardia with a  heart rate of 
180 beats per minute was detected (Figure 1 A). Negative 
T waves in V2–V6 (Figure 1 B), increased troponin level 
and long-lasting diabetes as a risk factor for atheroscle-
rosis with potential silent ischemia were indicators for 
coronary angiography. In urgent coronary angiography no 
significant coronary artery stenoses were confirmed. The 
tentative diagnosis of myocardial ischemia/injury due 
to epicardial coronary artery disease became doubtful. 
Transthoracic echocardiography was technically difficult 
due to suboptimal acoustic condition for the imaging. All 
heart valves were normal. Both ventricles and atria were 
non-dilated. Ejection fraction was 70%. The intraventricu-
lar septum at the basal segment was non-thickened (end 
systole 13 mm, end diastole 8 mm). Thickness of poste-
rior wall was normal (end systole 14 mm, end diastole 
7 mm). Importantly, the apical segment of the intraven-
tricular septum was hypertrophied (15–16 mm at end 
diastole; quality of imaging was suboptimal) suggesting 
the apical form of hypertrophic cardiomyopathy (HCM). 
In Doppler echocardiography moderate pulmonary hyper-
tension was detected. To confirm the presence of apical 
HCM cardiac magnetic resonance (CMR) with contrast 
agent (gadolinium) was performed. Cardiac magnetic res-
onance examination confirmed apical hypertrophy and 
excluded either ischemic injury or fibrotic area of myocar-
dium due to lack of regions of late contrast enhancement 
(Figures 1 C–F). No ventricular arrhythmias were observed 
in the ECG Holter recording. Both family history of sudden 
cardiac death and past history of syncope were negative.
Discussion
Cardiac magnetic resonance is a very useful diagnos-
tic modality in patients with non-definitive HCM due to 
technical difficulties in echocardiographic imaging. In 
about 20% of patients suspected with HCM the diagno-
sis is confirmed by CMR, especially when hypertrophy is 
localized in the apex or in the lateral wall. 
An increased (even persistently) level of troponin in 
HCM has been reported in several papers. A recent study 
[1] showed that high sensitive troponin T (hs-TnT) was 
detectable in three-quarters and elevated in one-quar-
ter of patients with HCM. Thus positive troponin test is 
a  frequent phenomenon in HCM. In obstructive HCM, 
TnI is correlated with left ventricular (LV) hypertrophy 
[2], and this biomarker is an independent predictor of 
the presence of myocardial fibrosis in CMR [3]. In our 
patient with apical HCM and an elevated level of TnI, 
late enhancement was absent and LV hypertrophy was 
relatively mild, limited to the apical region.
Interestingly, in the latest study of consecutive re-
ferrals of patients with suspected/known HCM to large 
tertiary centers, 18% of patients presented with apical 
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Figure 1. A – Supraventricular tachycardia at admission with negative T waves in V2–6. B – Sinus rhythm with 
negative T waves in V2–6. 
A
B
HCM phenotype [4]. Traditionally, apical HCM has been 
considered a rare variant of HCM, with a prevalence of 
approximately 7% and known more benign prognosis 
and lower risk of SCD [5].
Previously, it has been documented in HCM [6] that 
increased  troponin  release may be present in such pa-
tients  and is temporarily enhanced by exercise  and 
decreased with β-blockade. Probably in our patient su-
praventricular tachycardia mimics exercise and may be 
responsible for the increase of troponin.
Summing up, physicians should be aware of apical 
HCM in the case of patients with symptoms suggestive 
of acute coronary syndrome (electrocardiographic chang-
es, chest pain at rest, positive troponin test) and normal 
or near-normal coronary angiography. The lack of late 
enhancement in contrast CMR may be a useful non-inva-
sive method to exclude myocardial infarct.
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Figure 1. Cont. Cine steady-state free precession cardiac magnetic resonance images in three-chamber (C) and 
four-chamber (D) apical long axis views as well in short axis (E) apical view. Late gadolinium enhancement im-
aging (F) excluded the presence of acute ischemic injury and myocardial fibrosis. Note the presence of myocar-
dial hypertrophy in the apical segment of the lateral and anterior wall. The left ventricular ejection fraction was 
83%, end-diastolic volume 79 ml, end-systolic volume 14 ml, stroke volume 65 ml, and myocardial mass 92 g
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